- Report
- February 2026
- 262 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 462 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- January 2026
- 187 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 182 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 189 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 180 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 190 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 185 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 188 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 189 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 182 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 197 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 191 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 196 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 184 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 197 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 183 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 199 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 186 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- October 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more